Optimization of the dosage regimen of zoledronic acid with a kinetic-pharmacodynamic model and exposure-response analysis
Conclusion: Overall, the kinetic-pharmacodynamic model described changes of bone mineral density in different doses of zoledronic acid in vivo. And, the model and the exposure-response analysis also showed to provide the assessment of dose-response relationship for zoledronic acid. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - September 27, 2023 Category: Drugs & Pharmacology Source Type: research
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials
CONCLUSIONS: Our current results suggested that when considering both safety and efficacy, denosumab or teriparatide might be a better choice for women with postmenopausal osteoporosis.PMID:37750653 | DOI:10.26355/eurrev_202309_33586 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - September 26, 2023 Category: Drugs & Pharmacology Authors: W-Y Wang L-H Chen W-J Ma R-X You Source Type: research
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials
CONCLUSIONS: Our current results suggested that when considering both safety and efficacy, denosumab or teriparatide might be a better choice for women with postmenopausal osteoporosis.PMID:37750653 | DOI:10.26355/eurrev_202309_33586 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - September 26, 2023 Category: Drugs & Pharmacology Authors: W-Y Wang L-H Chen W-J Ma R-X You Source Type: research
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials
CONCLUSIONS: Our current results suggested that when considering both safety and efficacy, denosumab or teriparatide might be a better choice for women with postmenopausal osteoporosis.PMID:37750653 | DOI:10.26355/eurrev_202309_33586 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - September 26, 2023 Category: Drugs & Pharmacology Authors: W-Y Wang L-H Chen W-J Ma R-X You Source Type: research
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials
CONCLUSIONS: Our current results suggested that when considering both safety and efficacy, denosumab or teriparatide might be a better choice for women with postmenopausal osteoporosis.PMID:37750653 | DOI:10.26355/eurrev_202309_33586 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - September 26, 2023 Category: Drugs & Pharmacology Authors: W-Y Wang L-H Chen W-J Ma R-X You Source Type: research
Electrocardiogram Changes Following Intravenous Bisphosphonate Infusion: A Systematic Review and Meta ‐Analysis
ABSTRACTBisphosphonates are first-line treatments for several bone and mineral disorders. Studies have reported an increased incidence of serious atrial fibrillation in patients receiving bisphosphonates; however, uncertainty remains as to whether electrical disturbances are precipitated by bisphosphonates. We aimed to review the literature for studies reporting electrocardiogram (ECG) findings in patients receiving intravenous bisphosphonates for any indication. We searched MEDLINE and EMBASE from inception until January 14, 2023, for studies reporting ECG parameters after intravenous bisphosphonate infusion. We excluded ...
Source: Journal of Bone and Mineral Research - September 25, 2023 Category: Orthopaedics Authors: Alex Shoung,
Nicholas Shoung,
Rachael Hii,
Nitesh Nerlekar,
Peter R Ebeling,
Alexander J Rodr íguez Tags: Research Article Source Type: research
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis
CONCLUSION: Oncologists may have increased flexibility regarding the frequency of administration of BTT along with their choice of agent. Our study showed no significant difference in the prevention of overall SRE or development of BTT-associated harms between the BTT regimens evaluated.PMID:37735019 | DOI:10.1016/j.clbc.2023.08.008 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Athira Jayan Akshara Singareeka Raghavendra Roland Bassett Carlos H Barcenas Source Type: research
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis
CONCLUSION: Oncologists may have increased flexibility regarding the frequency of administration of BTT along with their choice of agent. Our study showed no significant difference in the prevention of overall SRE or development of BTT-associated harms between the BTT regimens evaluated.PMID:37735019 | DOI:10.1016/j.clbc.2023.08.008 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Athira Jayan Akshara Singareeka Raghavendra Roland Bassett Carlos H Barcenas Source Type: research
Preventive effect of teriparatide on medication-related osteonecrosis of the jaw in rats
In conclusion, TPD administration before tooth extraction helped reduce the occurrence of MRONJ in rats treated with zoledronic acid, confirming its preventative effects.PMID:37726385 | DOI:10.1038/s41598-023-42607-y (Source: Cancer Control)
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Kyeong-Mee Park Namkwon Lee Jaeyeon Kim Hyun Sil Kim Wonse Park Source Type: research
Association of prior treatment with nitrogen-containing bisphosphonates on outcomes of COVID-19 positive patients
ConclusionAmong older COVID-19 patients, prior exposure to N-BP including ZOL was not associated with a reduction in ICU admission, ventilator use, or death. (Source: Osteoporosis International)
Source: Osteoporosis International - September 13, 2023 Category: Orthopaedics Source Type: research
Electrocardiogram Changes Following Intravenous Bisphosphonate Infusion: A Systematic Review and Meta ‐Analysis
This article is protected by copyright. All rights reserved. (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - September 8, 2023 Category: Orthopaedics Authors: Alex Shoung,
Nicholas Shoung,
Rachael Hii,
Nitesh Nerlekar,
Peter R Ebeling,
Alexander J Rodr íguez Tags: Research Article Source Type: research
Zoledronic acid epigenetically alleviates high-glucose-suppressed osteogenic differentiation of MC3T3-E1 cells
CONCLUSIONS: In conclusion, under a high-glucose environment, zoledronic acid can modulate the expression of the RUNX2 transcription factor through epigenetic regulation.PMID:37667934 | DOI:10.26355/eurrev_202308_33409 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - September 5, 2023 Category: Drugs & Pharmacology Authors: H-L Chen J-P Hu J-F Li Q Li L Lan Source Type: research
